BIOTRON LIMITED(BIT.AU)
0.00+0.000.00%
Market data delayed 15 minutes
Login to post
- CommunityCommunity
- NewsNews
- ProfileProfile
- AnnouncementsAnnouncements
Grafa ·2024-04-05Biotron's (ASX:BIT) Phase 2 trial shows positive results for HIV treatmentBiotron's (ASX:BIT) Phase 2 trial shows positive results for HIV treatment
Biotechnology company Biotron reported preliminary results from its BIT225-010 Phase 2 trial in HIV-infected individuals. The data indicates BIT225's unique impact on HIV, targeting the virus in reservoir cells, surpassing current antiretroviral drugs. The 24-week trial assessed BIT225's safety, efficacy, and effect when added to standard therapy. The trial demonstrated BIT225's ability to rapidly reduce plasma virus levels, potentially affecting viral decay and latent reservoirs. Read More #News #ASX #Tech #BioTech #TechnologyCommentLikeShareReportRampageBullArmy ·2023-10-12$Biotron Ltd(BIT.AU)$ Expected high tomorrow$Biotron Ltd(BIT.AU)$ Expected high tomorrowCommentLikeShareReportRampageBullArmy ·2023-10-06$Biotron Ltd(BIT.AU)$ I will put some of my share on the market untill then you guys can join the board before it's too late.. untill then i will p...$Biotron Ltd(BIT.AU)$ I will put some of my share on the market untill then you guys can join the board before it's too late.. untill then i will pull back my share to let the flows in for BIOTRON:BITComment1ShareReportRampageBullArmy ·2023-10-06$Biotron Ltd(BIT.AU)$ Anyone who missed the train its not too late.. i will try to hold the bit as much as i can with my team.. do not wait too lon...$Biotron Ltd(BIT.AU)$ Anyone who missed the train its not too late.. i will try to hold the bit as much as i can with my team.. do not wait too long as im afraid I can't hold the BIT anymore 🤧CommentLikeShareReportRampageBullArmy ·2023-10-06$Biotron Ltd(BIT.AU)$ I'm so aware of BIT:ASX (Biotron) expected repeat it history on (2018) ⚡️👏🏻❤️🔥$Biotron Ltd(BIT.AU)$ I'm so aware of BIT:ASX (Biotron) expected repeat it history on (2018) ⚡️👏🏻❤️🔥CommentLikeShareReport- Biotron Ltd-Director Appointment Michael MedwayBiotron Ltd-Director Appointment Michael Medway
THOMSON REUTERS · 07-16
- Director Appointment Michael Medway-BIT.AXDirector Appointment Michael Medway-BIT.AX
Reuters · 07-16
- ASX ALERT-Hepatitis B Virus Program Update-BIT.AXASX ALERT-Hepatitis B Virus Program Update-BIT.AX
Reuters · 06-24
- Biotron Raises AU$1.3 Million via Entitlement Offer; Shares Decline 13%Biotron Raises AU$1.3 Million via Entitlement Offer; Shares Decline 13%
MT Newswires Live · 04-08
- Biotron raises $1.3M in rights issue
Grafa · 04-08
Biotron raises $1.3M in rights issue - Biotron Ltd-Dispatch of Rights Issue Offer DocumentsBiotron Ltd-Dispatch of Rights Issue Offer Documents
THOMSON REUTERS · 03-18
- Biotron Delays Opening of Rights Issue; Shares Hit All-Time LowBiotron Delays Opening of Rights Issue; Shares Hit All-Time Low
MT Newswires Live · 03-10
- Biotron Ltd-Delay in Offer Opening - BitrBiotron Ltd-Delay in Offer Opening - Bitr
THOMSON REUTERS · 03-10
- BRIEF-Biotron Says Renounceable Rights Issue To Raise Up To A$2.7 MillionBRIEF-Biotron Says Renounceable Rights Issue To Raise Up To A$2.7 Million
Reuters · 02-28
- Biotron Ltd-Proposed Issue of Securities - BitBiotron Ltd-Proposed Issue of Securities - Bit
THOMSON REUTERS · 02-27
- Biotron Ltd - Renounceable Rights Issue to Raise up to a$2.7 MlnBiotron Ltd - Renounceable Rights Issue to Raise up to a$2.7 Mln
THOMSON REUTERS · 02-27
- Biotron Ltd - Issue Price of 0.3 AU Cents per ShareBiotron Ltd - Issue Price of 0.3 AU Cents per Share
THOMSON REUTERS · 02-27
- ASX Biggest LosersASX Biggest Losers
MT Newswires Live · 02-07
Company Profile
Company NameBIOTRON LIMITEDMarketASXEstablishment Date- -Employees- -Office Location- -WebsiteZip Code- -Phone- -Fax- -IntroductionBiotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, including Dengue, Zika, Influenza, Ebola, and SARs. Biotron Limited is based in North Ryde, Australia.
- 1D
- 5D
- Day
- Week
- Month
Loading ...
High
0.00
Open
0.00
Volume%
3.20
Low
0.00
Close
0.00
T/O Rate
0.41%